AbbVie

News

AbbVie files Qulipta for chronic migraine prevention

AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.

News

AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease appro...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new ind

News

AbbVie adds to Vraylar data as FDA considers depression use

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indicatio

News

AbbVie files continuous Parkinson's therapy ABBV-951 in US

AbbVie has filed for approval of its therapy for Parkinson's disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current drugs that often fail to

News

AbbVie and Cugene partner to tackle autoimmune diseases

AbbVie and Cugene have teamed up to research autoimmune diseases and cancer in an exclusive worldwide agreement.

News

Allergan, Teva considering $5bn play to shake off opioid han...

AbbVie's Allergan subsidiary and Teva are reportedly considering making a $5 billion-plus offer to try to bring opioid liability lawsuits to a conclusion.

AbbVie files Qulipta for chronic migraine prevention

AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease appro...

AbbVie adds to Vraylar data as FDA considers depression use

AbbVie files continuous Parkinson's therapy ABBV-951 in US

AbbVie and Cugene partner to tackle autoimmune diseases

Allergan, Teva considering $5bn play to shake off opioid han...

Novo Nordisk fight with KBP Bio will go to arbitration

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks